Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation

Trial Profile

Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 May 2017

At a glance

  • Drugs Dabigatran etexilate (Primary)
  • Indications Intracranial embolism
  • Focus Therapeutic Use
  • Acronyms ODIn-AF
  • Most Recent Events

    • 09 Sep 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
    • 12 Aug 2015 Planned End Date changed from 1 Jun 2016 to 1 Aug 2019, according to ClinicalTrials.gov record.
    • 12 Aug 2015 Planned primary completion date changed from 1 Jun 2016 to 1 Aug 2018, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top